SP
ADAP

Syncona Portfolio’s Adaptimmune Therapeutics ADAP Stock Holding History

Syncona Portfolio’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,377,294
Closed -$1.09M – 3
2023
Q4 		$1.09M Hold
1,377,294
– – 0.69% 4
2023
Q3 		$1.07M Hold
1,377,294
– – 1.6% 4
2023
Q2 		$1.27M Hold
1,377,294
– – 1.92% 4
2023
Q1 		$1.5M Hold
1,377,294
– – 2.44% 4
2022
Q4 		$2.01M Hold
1,377,294
– – 3.19% 4
2022
Q3 		$1.48M Hold
1,377,294
– – 2.57% 4
2022
Q2 		$2.34M Hold
1,377,294
– – 3.33% 4
2022
Q1 		$5.17M Hold
1,377,294
– – 4.93% 4
2021
Q4 		$5.17M Buy
+1,377,294
New +$6.27M 4.93% 4

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Syncona Portfolio's ADAP Position: Q1 2024 in Review

Syncona Portfolio sold out of Adaptimmune Therapeutics (ADAP) in Q1 2024, closing a stake of 1,377,294 shares — an estimated $1.09M sold.

Syncona Portfolio first reported a position in ADAP in Q4 2021 and held it in 9 quarters. The position peaked at $5.17M in Q1 2022. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2024.

  • Syncona Portfolio reported no remaining Adaptimmune Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Syncona Portfolio sold 1,377,294 Adaptimmune Therapeutics shares in Q1 2024, an estimated $1.09M.
  • Syncona Portfolio first reported a position in Adaptimmune Therapeutics in Q4 2021 and held it in 9 quarters.
  • Syncona Portfolio's Adaptimmune Therapeutics position peaked at $5.17M in Q1 2022.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2024.

Based on Syncona Portfolio's 13F filing for Q1 2024, filed 7 May 2024.